View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/FDA | RIN: 0910-AH68 | Publication ID: Spring 2018 |
Title: Medication Guides; Patient Medication Information | |
Abstract:
The proposed rule would amend FDA medication guide regulations to require a new form of patient labeling, Patient Medication Information, for submission to and review by the FDA for human prescription drug products and certain blood products used, dispensed, or administered on an outpatient basis. The proposed rule would include requirements for Patient Medication Information development and distribution. The proposed rule would require clear and concisely written prescription drug product information presented in a consistent and easily understood format to help patients use their prescription drug products safely and effectively. |
|
Agency: Department of Health and Human Services(HHS) | Priority: Economically Significant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Proposed Rule Stage |
Major: Undetermined | Unfunded Mandates: No |
EO 13771 Designation: Regulatory | |
CFR Citation: 21 CFR 208 21 CFR 606.123 (new) 21 CFR 310.501 and 310.515 (removal) 21 CFR 201.57 (a)(18) (revision) 21 CFR 201.809(f)(2) (revision) 21 CFR 314.70(b)(2)(v)(B) (revision) 21 CFR 610.60(a)(7) (removal) ... (To search for a specific CFR, visit the Code of Federal Regulations.) | |
Legal Authority: 21 U.S.C 321 et seq. 42 U.S.C. 262 42 U.S.C. 264 21 U.S.C. 371 |
Legal Deadline:
None |
||||||
Timetable:
|
Regulatory Flexibility Analysis Required: Yes | Government Levels Affected: None |
Small Entities Affected: Businesses | Federalism: No |
Included in the Regulatory Plan: Yes | |
RIN Data Printed in the FR: Yes | |
Agency Contact: Chris Wheeler Supervisory Project Manager Department of Health and Human Services Food and Drug Administration 10903 New Hampshire Avenue, Building 51, Room 3330, Silver Spring, MD 20993 Phone:301 796-0151 Email: cderomp@fda.hhs.gov |